Press

2021-11-10

Click Therapeutics to Participate in the BTIG Digital Health Forum

2021-10-22

Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth Partners and Accelmed Partners

2021-04-07

Click Therapeutics Expands its Leadership with Executive and Board Appointments

2021-03-09

Click Therapeutics Announces Collaboration with youturn to Expand Access to Clinically Validated Smoking Cessation Program Clickotine®

2021-02-24

Otsuka and Click Therapeutics Initiate First-of-its-Kind Fully Remote Clinical Trial Using Digital Therapeutics as Adjunctive Therapy in Adults With Major Depressive Disorder

2020-12-01

Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations

2020-11-19

Click Therapeutics Announces that Solera Health will Provide Clinically Validated Smoking-Cessation Program Clickotine® to Blue Shield of California Members

2020-09-11

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

2020-05-11

Click Therapeutics Announces Participation in Upcoming Investor Conferences in May and June

2020-04-23

Click Therapeutics Launches New Brand Identity and Redesigned Website

2020-04-20

Magellan Health and Click Therapeutics Launch Fully Digital, Integrated and Comprehensive Smoking Cessation Program

2020-02-24

Click Therapeutics to Present at the Cowen and Company 40th Annual Healthcare Conference

2020-02-11

Click Therapeutics Announces Appointment of Top Healthcare Executives Muzammil Mansuri and Jeffrey Berkowitz as Senior Strategic Advisors and Formation of Payer Advisory Board

2019-10-16

Click Therapeutics, Inc. Honored by Goldman Sachs for Entrepreneurship

2019-09-04

Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer

2019-01-03

Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder

2018-10-02

Click Therapeutics Expands Executive Team with Chief Medical Officer and Chief Strategy Officer

2018-07-23

Sanofi Ventures Leads $17 Million Financing of Click Therapeutics

2018-06-06

Click Therapeutics Announces Multiple Publications Supporting Its Digital Therapeutic for Major Depressive Disorder; Seeking FDA Clearance

2018-05-18

Click Therapeutics Awarded National Institutes of Health (NIH) Grant for Clickotine® Digital Therapeutic Study

2018-02-14

Click Therapeutics Announces the Release of the Click Affective Pictures Set (CAPS) to Researchers Globally

2017-04-25

Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder

2017-03-20

Click Therapeutics Presents Data on Increased Efficacy of a Digital Therapeutics™ Program for Smoking Cessation at Six-Month Mark of Clinical Trial

2016-09-21

Click Therapeutics™ Reports Preliminary Results of a 416-Participant Clinical Study Demonstrating Exceptional Engagement and Efficacy of Clickotine®, a Patent-Pending Digital Therapeutics™ Program for Smoking Cessation